JAK Inhibitor Selectivity and Dose-Related Toxicity
Panelists discuss how the varying selectivity of JAK inhibitors—such as tofacitinib's broad inhibition of JAK1/JAK2/JAK3, baricitinib's inhibition of JAK1/JAK2, and upadacitinib's focus on JAK1—affects dose-related toxicity and overall treatment safety.
Read More
JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety
Panelists discuss how JAK inhibitors and TNF inhibitors differ in administration, efficacy, and safety due to their unique characteristics and mechanisms of action, with further variations in binding activities within the TNFi class impacting clinical outcomes.
Read More
Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons
Panelists discuss how head-to-head clinical trial data shape their treatment decisions, the significance of consistent remission rates across different patient populations, and the frequency with which remission data influence their choices to switch therapies.
Read More
Advanced Treatment Options for RA: Exploring the Data
Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).
Read More
Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
Experts discuss American College of Rheumatology guidelines on transitioning patients from TNF inhibitors to non-TNF targeted therapies like Janus kinase inhibitors, as well as factors influencing treatment switching decisions in clinical practice.
Read More
Achieving Low Disease Activity and Remission: Managing Patient Expectations
Experts discuss strategies for achieving low disease activity or remission in patients, including steps taken in clinical practice and methods for managing patient expectations regarding treatment outcomes.
Read More
A panel of medical experts explore how to evaluate and adjust rheumatoid arthritis treatment by adhering to ACR guidelines for conventional synthetic DMARDs and advanced therapies, focusing on optimizing patient care and treatment outcomes.
Read More
Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments
Medical experts explore how patient perceptions of rheumatoid arthritis can differ from disease activity assessments and provide an example of hidden symptoms revealed through further probing, along with the impact of therapy adjustments on achieving remission.
Read More
Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis
A panel of medical experts discuss complications and prognostic factors in uncontrolled rheumatoid arthritis.
Read More
Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice
A panel of medical experts discuss the prevalence and management of poorly controlled rheumatoid arthritis in clinical practice.
Read More
Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission
A panel of medical experts discuss how clinical guidelines currently define clinical remission, as well as the clinical and economic benefits associated with clinical remission.
Read More